Mesoblast Limited (MSB.AX)
AUD 3.05
(54.04%)
AUD 3.05
(54.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -62.82 Million USD | -7.3% |
| 2023 | -58.55 Million USD | 15.08% |
| 2022 | -76.57 Million USD | 28.84% |
| 2021 | -107.6 Million USD | -42.7% |
| 2020 | -75.4 Million USD | 7.09% |
| 2019 | -78.06 Million USD | -8.67% |
| 2018 | -74.68 Million USD | 16.97% |
| 2017 | -87.15 Million USD | -220.42% |
| 2016 | -28.07 Million USD | 75.77% |
| 2015 | -90.19 Million USD | -72.91% |
| 2014 | -67 Million USD | -12.99% |
| 2013 | -59.3 Million USD | -125.25% |
| 2012 | -48.34 Million USD | -128.48% |
| 2011 | 92.43 Million USD | 942.36% |
| 2010 | -10.97 Million USD | -17.88% |
| 2009 | -9.3 Million USD | -19.61% |
| 2008 | -7.78 Million USD | 10.18% |
| 2007 | -6.95 Million USD | -6.39% |
| 2006 | -8.14 Million USD | -505.9% |
| 2005 | -1.34 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -12.78 Million USD | 0.0% |
| 2024 Q1 | -12.78 Million USD | 27.63% |
| 2024 FY | - USD | 20.83% |
| 2023 Q3 | -13.47 Million USD | 32.73% |
| 2023 Q4 | -17.65 Million USD | -31.07% |
| 2023 Q1 | -14.9 Million USD | 20.17% |
| 2023 Q2 | -20.02 Million USD | -34.42% |
| 2023 FY | - USD | 15.08% |
| 2022 Q4 | -18.66 Million USD | -2.41% |
| 2022 Q3 | -18.22 Million USD | 22.56% |
| 2022 Q2 | -23.53 Million USD | -21.78% |
| 2022 FY | - USD | 28.84% |
| 2022 Q1 | -19.32 Million USD | -6.39% |
| 2021 Q4 | -18.16 Million USD | 26.82% |
| 2021 Q2 | -26.31 Million USD | 29.94% |
| 2021 Q1 | -37.56 Million USD | -21.23% |
| 2021 Q3 | -24.82 Million USD | 5.67% |
| 2021 FY | - USD | -42.7% |
| 2020 Q3 | -14.57 Million USD | 36.22% |
| 2020 Q4 | -30.98 Million USD | -112.59% |
| 2020 FY | - USD | 7.09% |
| 2020 Q2 | -22.85 Million USD | -648.2% |
| 2020 Q1 | -3.05 Million USD | 82.62% |
| 2019 Q2 | -23.65 Million USD | -45.75% |
| 2019 FY | - USD | -8.67% |
| 2019 Q3 | -21.68 Million USD | 8.34% |
| 2019 Q4 | -17.56 Million USD | 18.97% |
| 2019 Q1 | -16.22 Million USD | 29.77% |
| 2018 Q3 | -23.6 Million USD | -203.51% |
| 2018 FY | - USD | 16.97% |
| 2018 Q4 | -23.11 Million USD | 2.11% |
| 2018 Q2 | -7.77 Million USD | 72.64% |
| 2018 Q1 | -28.42 Million USD | -84.1% |
| 2017 FY | - USD | -220.42% |
| 2017 Q1 | -21.1 Million USD | -166.78% |
| 2017 Q2 | -22.07 Million USD | -4.61% |
| 2017 Q3 | -21.22 Million USD | 3.86% |
| 2017 Q4 | -15.44 Million USD | 27.25% |
| 2016 FY | - USD | 75.77% |
| 2016 Q1 | -13.76 Million USD | 72.91% |
| 2016 Q2 | -20.39 Million USD | -48.1% |
| 2016 Q4 | 31.6 Million USD | 246.93% |
| 2016 Q3 | -21.51 Million USD | -5.49% |
| 2015 Q3 | -20.08 Million USD | 21.96% |
| 2015 FY | - USD | -72.91% |
| 2015 Q4 | -50.83 Million USD | -153.09% |
| 2015 Q2 | -25.73 Million USD | -59.19% |
| 2015 Q1 | -16.16 Million USD | 11.7% |
| 2014 Q3 | -18.55 Million USD | -1.49% |
| 2014 Q4 | -18.3 Million USD | 1.35% |
| 2014 FY | - USD | -12.99% |
| 2014 Q1 | -10.24 Million USD | 27.75% |
| 2014 Q2 | -18.28 Million USD | -78.54% |
| 2013 Q2 | -14.25 Million USD | -0.06% |
| 2013 Q4 | -14.17 Million USD | 12.05% |
| 2013 Q3 | -16.11 Million USD | -13.08% |
| 2013 FY | - USD | -125.25% |
| 2013 Q1 | -14.24 Million USD | 0.0% |
| 2012 FY | - USD | -128.48% |
| 2011 FY | - USD | 942.36% |
| 2010 FY | - USD | -17.88% |
| 2009 FY | - USD | -19.61% |
| 2008 FY | - USD | 10.18% |
| 2007 FY | - USD | -6.39% |
| 2006 FY | - USD | -505.9% |
| 2005 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 705.496% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -4212.8% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -2011.706% |
| Zelira Therapeutics Limited | -36.44 Million AUD | -72.396% |
| Biome Australia Limited | -1.57 Million AUD | -3880.546% |
| Patrys Limited | -3.49 Million AUD | -1698.976% |
| Orthocell Limited | -11.68 Million AUD | -437.817% |
| Imugene Limited | -147.97 Million AUD | 57.546% |
| Noxopharm Limited | -5.94 Million AUD | -956.65% |
| PYC Therapeutics Limited | -38.11 Million AUD | -64.814% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | -455.966% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -774.278% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | -696.506% |
| Cynata Therapeutics Limited | -9.95 Million AUD | -531.374% |
| CSL Limited | 4.73 Billion AUD | 101.327% |
| Arovella Therapeutics Limited | -8.83 Million AUD | -611.218% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | -351.335% |
| Race Oncology Limited | -14.2 Million AUD | -342.31% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 221.133% |
| Starpharma Holdings Limited | -12.57 Million AUD | -399.507% |
| Nanollose Limited | -1.14 Million AUD | -5372.859% |
| Memphasys Limited | -3.3 Million AUD | -1799.284% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -8620.076% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -3397.385% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -1277.819% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -2129.254% |
| Nyrada Inc. | -4.59 Million AUD | -1266.846% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | -40.709% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 373.548% |
| Dimerix Limited | -24.95 Million AUD | -151.709% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 131.528% |
| PharmAust Limited | -9.45 Million AUD | -564.673% |
| Immutep Limited | -42.87 Million AUD | -46.525% |
| BTC Health Limited | 1.05 Million AUD | 6053.167% |
| Acrux Limited | -7.93 Million AUD | -692.12% |
| Alterity Therapeutics Limited | -19.57 Million AUD | -220.991% |
| Biotron Limited | -5.04 Million AUD | -1146.475% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | -38.449% |
| Tissue Repair Ltd | -5.77 Million AUD | -987.845% |
| AdAlta Limited | -5.3 Million AUD | -1084.736% |
| Hexima Limited | -995.54 Thousand AUD | -6210.426% |
| AnteoTech Limited | -11.57 Million AUD | -442.936% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 2.659% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | -194.196% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -1837.481% |
| Actinogen Medical Limited | -12.92 Million AUD | -386.202% |
| Immuron Limited | -6.19 Million AUD | -914.525% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -3210.671% |